Mark J. Smyth

118.6k total citations · 40 hit papers
595 papers, 81.6k citations indexed

About

Mark J. Smyth is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Mark J. Smyth has authored 595 papers receiving a total of 81.6k indexed citations (citations by other indexed papers that have themselves been cited), including 452 papers in Immunology, 265 papers in Oncology and 128 papers in Molecular Biology. Recurrent topics in Mark J. Smyth's work include Immune Cell Function and Interaction (339 papers), T-cell and B-cell Immunology (173 papers) and Immunotherapy and Immune Responses (162 papers). Mark J. Smyth is often cited by papers focused on Immune Cell Function and Interaction (339 papers), T-cell and B-cell Immunology (173 papers) and Immunotherapy and Immune Responses (162 papers). Mark J. Smyth collaborates with scholars based in Australia, United States and Japan. Mark J. Smyth's co-authors include Robert D. Schreiber, Michele W.L. Teng, Joseph A. Trapani, Lloyd J. Old, Dale I. Godfrey, Yoshihiro Hayakawa, Hideo Yagita∥, Kazuyoshi Takeda, Shin Foong Ngiow and Jeremy B. Swann and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Mark J. Smyth

589 papers receiving 80.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

2011 4.6k citations Robert D. Schreiber, Mark J. Smyth et al. profile →
Natural Innate and Adaptive Immunity to Cancer

2011 1.5k citations Michael H. Kershaw, Robert D. Schreiber et al. profile →
Cancer immunoediting and resistance to T cell-based immunotherapy

2018 1.3k citations Michele W.L. Teng, Mark J. Smyth et al. profile →
Classifying Cancers Based on T-cell Infiltration and PD-L1

2015 1.1k citations Michele W.L. Teng, Shin Foong Ngiow et al. Cancer Research profile →
New insights into cancer immunoediting and its three component phases — elimination, equilibrium and escape

2014 1.1k citations Deepak Mittal, Robert D. Schreiber et al. profile →
Immune surveillance of tumors

2007 1.1k citations Jeremy B. Swann, Mark J. Smyth profile →
Adaptive immunity maintains occult cancer in an equilibrium state

2007 1.0k citations Catherine Koebel, William Vermi et al. profile →
Translational biology of osteosarcoma

2014 978 citations Maya Kansara, Michele W.L. Teng et al. profile →
Type I interferons in anticancer immunity

2015 964 citations Laurence Zitvogel, Mark J. Smyth et al. profile →
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

2014 956 citations Mark J. Smyth et al. profile →
NKT cells: what's in a name?

2004 955 citations Mark J. Smyth et al. profile →
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

2012 932 citations Cora D. Arthur, J. Michael White et al. profile →
Functional significance of the perforin/granzyme cell death pathway

2002 929 citations Joseph A. Trapani, Mark J. Smyth profile →
Targeting natural killer cells in cancer immunotherapy

2016 832 citations Mark J. Smyth et al. profile →
Combination cancer immunotherapies tailored to the tumour microenvironment

2015 738 citations Mark J. Smyth, Shin Foong Ngiow et al. profile →
The TRAIL apoptotic pathway in cancer onset, progression and therapy

2008 712 citations Mark J. Smyth et al. profile →
NKT cells: facts, functions and fallacies

2000 704 citations Mark J. Smyth et al. profile →
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

2013 681 citations Laurence Zitvogel, Mark J. Smyth et al. profile →
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases

2015 639 citations Michele W.L. Teng, Mark J. Smyth et al. profile →
Clinical relevance of host immunity in breast cancer: from TILs to the clinic

2015 638 citations Phillip K. Darcy, Mark J. Smyth et al. profile →
Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells

2000 628 citations Mark J. Smyth, Shayna E.A. Street et al. The Journal of Experimental Medicine profile →
Cancer Immunosurveillance and Immunoediting: The Roles of Immunity in Suppressing Tumor Development and Shaping Tumor Immunogenicity

2006 620 citations Mark J. Smyth, Robert D. Schreiber et al. profile →
IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses

2010 608 citations Mark J. Smyth et al. The Journal of Experimental Medicine profile →
Targeting immunosuppressive adenosine in cancer

2017 608 citations Dipti Vijayan, Arabella Young et al. profile →
IL-21 regulates germinal center B cell differentiation and proliferation through a B cell–intrinsic mechanism

2010 599 citations Mark J. Smyth et al. The Journal of Experimental Medicine profile →
Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells

2001 595 citations Kazuyoshi Takeda, Yoshihiro Hayakawa et al. profile →
New aspects of natural-killer-cell surveillance and therapy of cancer

2002 589 citations Mark J. Smyth, Yoshihiro Hayakawa et al. profile →
A fresh look at tumor immunosurveillance and immunotherapy

2001 585 citations Mark J. Smyth, Joseph A. Trapani et al. profile →
CD27 Dissects Mature NK Cells into Two Subsets with Distinct Responsiveness and Migratory Capacity

2006 582 citations Yoshihiro Hayakawa, Mark J. Smyth profile →
Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

2013 571 citations Paul A. Beavis, Nicole M. Haynes et al. Clinical Cancer Research profile →
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

2016 569 citations Jing Liu, Stephen J. Blake et al. Cancer Discovery profile →
Control of Metastasis by NK Cells

2017 548 citations Mark J. Smyth et al. profile →
Activation of NK cell cytotoxicity

2004 514 citations Mark J. Smyth, Erika Cretney et al. profile →
TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway

2016 493 citations Mark J. Smyth et al. profile →
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

2010 479 citations John Stagg, Upulie Divisekera et al. Proceedings of the National Academy of Sciences profile →
Resistance to PD1/PDL1 checkpoint inhibition

2016 429 citations Michele W.L. Teng, Mark J. Smyth et al. profile →
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

2013 387 citations Paul A. Beavis, Phillip K. Darcy et al. Proceedings of the National Academy of Sciences profile →
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment

2019 379 citations Mark J. Smyth et al. profile →
The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies

2020 364 citations Mark J. Smyth et al. profile →
ATP and cancer immunosurveillance

2021 160 citations Takahiro Yamazaki, Mark J. Smyth et al. profile →

Peers

Countries citing papers authored by Mark J. Smyth

Since Specialization

Citations

This map shows the geographic impact of Mark J. Smyth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Smyth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Smyth more than expected).

Fields of papers citing papers by Mark J. Smyth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Smyth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Smyth. The network helps show where Mark J. Smyth may publish in the future.

Co-authorship network of co-authors of Mark J. Smyth

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. Smyth. A scholar is included among the top collaborators of Mark J. Smyth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. Smyth. Mark J. Smyth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23 2019 ·Cancer Discovery ·Maya Kansara, (unknown), Puiyi Pang, Aurélie Dutour, Lisa Mirabello, Francine Acher, Jean‐Philippe Pin, Elizabeth G. Demicco, Juming Yan, Michele W.L. Teng, Mark J. Smyth, David M. Thomas	35
2	Experimental Lung Metastases in Mice Are More Effectively Inhibited by Blockade of IL23R than IL23 2018 ·Cancer Immunology Research ·Juming Yan, Stacey Allen, Dipti Vijayan, Xian-Yang Li, Heidi Harjunpää, Kazuyoshi Takeda, Jing Liu, J. Daniel, Mark J. Smyth, Michele W.L. Teng	13
3	Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer 2017 ·Cancer Research ·Jennifer D. Brooks, Bettina Fleischmann-Mundt, Norman Woller, (unknown), Silvia Ribback, (unknown), İhsan Ekin Demir, (unknown), Güralp O. Ceyhan, Michael P. Manns, Thomas Wirth, Stefan Kubicka, Günter Bernhardt, Mark J. Smyth, Diego F. Calvisi, Engin Gürlevik, Florian Kühnel	55
4	Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell–Rich Tumor 2016 ·Cancer Research ·Shin Foong Ngiow, Arabella Young, Stephen J. Blake, Geoffrey R. Hill, Hideo Yagita∥, Michele W.L. Teng, Alan J. Korman, Mark J. Smyth	72
5	Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer 2016 ·Cancer Research ·Jing Liu, Stephen J. Blake, Heidi Harjunpää, Kirsten A. Fairfax, Michelle C.R. Yong, Stacey Allen, Holbrook E. Kohrt, Kazuyoshi Takeda, Mark J. Smyth, Michele W.L. Teng	76
6	Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy 2016 ·Cancer Discovery ·Stephen J. Blake, Kimberley Stannard, Jing Liu, Stacey Allen, Michelle C.R. Yong, Deepak Mittal, Amelia Roman Aguilera, John J. Miles, Viviana P. Lutzky, Lucas Ferrari de Andrade, Ludovic Martinet, Marco Colonna, Kazuyoshi Takeda, Florian Kühnel, Engin Gürlevik, Günter Bernhardt, Michele W.L. Teng, Mark J. Smyth	187
7	A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1 2015 ·Cancer Research ·Shin Foong Ngiow, Arabella Young, Nicolas Jacquelot, Takahiro Yamazaki, David Enot, Laurence Zitvogel, Mark J. Smyth	184
8	Combined Anti-CD40 and Anti–IL-23 Monoclonal Antibody Therapy Effectively Suppresses Tumor Growth and Metastases 2014 ·Cancer Research ·Bianca von Scheidt, (unknown), Michelle C.R. Yong, Yu Zhang, Jennifer E. Towne, Mark J. Smyth, Michele W.L. Teng	30
9	Contribution of Thy1 ⁺ NK cells to protective IFN-γ production during Salmonella Typhimurium infections 2013 ·Proceedings of the National Academy of Sciences ·Andreas Kupz, Timothy A. Scott, Gabrielle T. Belz, Daniel M. Andrews, (unknown), Andrew M. Lew, Andrëw G. Brööks, Mark J. Smyth, Roy Curtiss, Sammy Bedoui, Richard A. Strugnell	80
10	NLRP3 Suppresses NK Cell–Mediated Responses to Carcinogen-Induced Tumors and Metastases 2012 ·Cancer Research ·Melvyn T. Chow, Jaclyn Sceneay, Christophe Paget, Christina S.F. Wong, Helene Duret, Jürg Tschopp, Andreas Möller, Mark J. Smyth	155
11	Cancer immunoediting by the innate immune system in the absence of adaptive immunity 2012 ·The Journal of Experimental Medicine ·Timothy E. O’Sullivan, Robert Saddawi‐Konefka, William Vermi, Catherine Koebel, Cora D. Arthur, J. Michael White, Ravindra Uppaluri, Daniel M. Andrews, Shin Foong Ngiow, Michele W.L. Teng, Mark J. Smyth, Robert D. Schreiber, Jack D. Bui	257
12	Primary Tumor Hypoxia Recruits CD11b+/Ly6Cmed/Ly6G+ Immune Suppressor Cells and Compromises NK Cell Cytotoxicity in the Premetastatic Niche 2012 ·Cancer Research ·Jaclyn Sceneay, Melvyn T. Chow, Anna Chen, Heloise M. Halse, Christina S.F. Wong, Daniel M. Andrews, Erica K. Sloan, Belinda S. Parker, David D.L. Bowtell, Mark J. Smyth, Andreas Möller	296
13	CD73-Deficient Mice Are Resistant to Carcinogenesis 2012 ·Cancer Research ·John Stagg, Paul A. Beavis, Upulie Divisekera, Mira C.P. Liu, Andreas Möller, Phillip K. Darcy, Mark J. Smyth	174
14	Conditional Regulatory T-Cell Depletion Releases Adaptive Immunity Preventing Carcinogenesis and Suppressing Established Tumor Growth 2010 ·Cancer Research ·Michele W.L. Teng, Shin Foong Ngiow, Bianca von Scheidt, Nicole M. McLaughlin, Tim Sparwasser, Mark J. Smyth	149
15	Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice 2009 ·Clinical Cancer Research ·Jennifer A. Westwood, Nicole M. Haynes, Janelle Sharkey, Nicole M. McLaughlin, Hollie J. Pegram, Reto A. Schwendener, Mark J. Smyth, Phillip K. Darcy, Michael H. Kershaw	20
16	Interleukin 21 Enhances Antibody-Mediated Tumor Rejection 2008 ·Cancer Research ·Mark J. Smyth, Michele W.L. Teng, Janelle Sharkey, Jennifer A. Westwood, Nicole M. Haynes, Hideo Yagita∥, Kazuyoshi Takeda, Pallavur V. Sivakumar, Michael H. Kershaw	23
17	Host Perforin Reduces Tumor Number but Does Not Increase Survival in Oncogene-Driven Mammary Adenocarcinoma 2007 ·Cancer Research ·Shayna E.A. Street, Nadeen Zerafa, Manuela Iezzi, Jennifer A. Westwood, John Stagg, Piero Musiani, Mark J. Smyth	39
18	BAFF and MyD88 signals promote a lupuslike disease independent of T cells 2007 ·The Journal of Experimental Medicine ·Joanna R. Groom, Carrie A. Fletcher, Stacey N. Walters, Shane T. Grey, Sally V. Watt, Matthew J. Sweet, Mark J. Smyth, Charles R. Mackay, Fabienne Mackay	302
19	Sustained Antigen-Specific Antitumor Recall Response Mediated by Gene-Modified CD4+ T Helper-1 and CD8+ T Cells 2007 ·Cancer Research ·Maria Moeller, Michael H. Kershaw, (unknown), Jennifer A. Westwood, Joseph A. Trapani, Mark J. Smyth, Phillip K. Darcy	55
20	NKG2D function protects the host from tumor initiation 2005 ·The Journal of Experimental Medicine ·Mark J. Smyth, Jeremy B. Swann, Erika Cretney, Nadeen Zerafa, Wayne M. Yokoyama, Yoshihiro Hayakawa	261

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact